Floatz logo

Alglucosidase Alfa

Glycogen Storage Disease Due To Acid Maltase Deficiency, Infantile Onset

Genzyme, a Sanofi Companyprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Glycogen Storage Disease Due To Acid Maltase Deficiency, Infantile Onset cohort.

Asset / SponsorPhaseRating
Miglustat
Amicus Therapeutics
Phase 3B
Cipaglucosidase Alfa
Amicus Therapeutics
Phase 3B
gc301
GeneCradle Inc
Phase 1/2CCC
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN)
University of California, San Francisco
Phase 1CC

Same molecule, other indications

Alglucosidase Alfa is also rated in:

glycogen storage disease IIActive
A
Indicative · Phase 4
80 / 100
View asset →
glycogen storage disease due to acid maltase deficiency, late-onsetActive
BBB
Indicative · Phase 4
78 / 100
View asset →
disorder of glycogen metabolismDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →